Darriet Frederic, Zaim Morteza, Corbel Vincent
Institut de Recherche pour le Développement, Laboratoire de Lutte Contre les Insectes Nuisibles, 911 Avenue Agropolis, BP 64501, 34934 Montpellier 5, France.
J Am Mosq Control Assoc. 2008 Mar;24(1):123-6. doi: 10.2987/5626.1.
In this study, the activity of cyromazine was evaluated following WHO standard procedures against susceptible and resistant mosquito strains of Anopheles gambiae, Culex quinquefasciatus, and Aedes aegypti. The dose for 50% and 90% inhibition of adult emergence (IE50 and IE90) ranged from 0.028 mg/liter to 0.17 mg/liter and from 0.075 mg/liter to 0.42 mg/liter, respectively. The effects of cyromazine were closer to that of chitin synthesis inhibitors rather than that of juvenile hormone analogues, with only 10-20% pupal mortality. The toxicity of cyromazine was not strongly affected by the presence of common resistance mechanism, i.e., Kdr mutation and Ace.1(R) (resistance ratio from 0.5 to 2.3). The absence of cross resistance with common insecticides (pyrethroids, carbamates, organophosphates) makes cyromazine a potential candidate for disease vector control, especially for the management of insecticide resistance.
在本研究中,按照世界卫生组织的标准程序,评估了灭蝇胺对冈比亚按蚊、致倦库蚊和埃及伊蚊的敏感及抗性品系的活性。抑制成虫羽化50%和90%的剂量(IE50和IE90)分别为0.028毫克/升至0.17毫克/升以及0.075毫克/升至0.42毫克/升。灭蝇胺的作用更接近几丁质合成抑制剂而非保幼激素类似物,蛹死亡率仅为10%-20%。常见抗性机制(即击倒抗性突变和Ace.1(R))的存在对灭蝇胺的毒性影响不大(抗性比为0.5至2.3)。与常用杀虫剂(拟除虫菊酯类、氨基甲酸酯类、有机磷类)不存在交叉抗性,这使得灭蝇胺成为病媒控制的潜在候选药物,尤其是用于管理杀虫剂抗性。